The philosophy underpinning the patient-focused drug development (PFDD) movement – that it's important to find out what symptoms are most bothersome to patients, and what they would like to see in new treatments – is increasingly being embraced by drug developers as they plan their clinical programs for new compounds.
Below are two examples of how the growing attention to the importance of the patient voice, coupled with the US FDA's own PFDD initiatives, have impacted recent drug development programs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?